Ken Griffin
SGMT icon

Ken Griffin’s Sagimet Biosciences SGMT Stock Holding History

Ken Griffin’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$396K Buy
75,700
+7,600
+11% +$42.4K ﹤0.01% 9842
2025
Q4 		$403K Sell
68,100
-43,100
-39% -$310K ﹤0.01% 9523
2025
Q3 		$763K Buy
111,200
+28,900
+35% +$234K ﹤0.01% 8144
2025
Q2 		$627K Buy
82,300
+33,100
+67% +$140K ﹤0.01% 8102
2025
Q1 		$160K Sell
49,200
-23,200
-32% -$97.3K ﹤0.01% 10773
2024
Q4 		$326K Buy
72,400
+6,000
+9% +$30.4K ﹤0.01% 9483
2024
Q3 		$184K Buy
66,400
+58,200
+710% +$179K ﹤0.01% 10278
2024
Q2 		$28K Buy
+8,200
New +$37.6K ﹤0.01% 12334

Other funds holding SGMT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Ken Griffin's SGMT Position: Q1 2026 in Review

Ken Griffin increased its Sagimet Biosciences (SGMT) stake by 8% in Q1 2026, buying an estimated $28.2K and bringing the position to 68,173 shares worth $356K. The position accounts for ﹤0.01% of the portfolio, ranked #10083.

Ken Griffin first reported a position in SGMT in Q3 2023 and has held it in 10 quarters since. The position peaked at $4.09M in Q2 2024. 88 funds tracked by Wall St. Rank hold SGMT as of Q1 2026.

  • Ken Griffin held 68,173 shares of Sagimet Biosciences worth $356K as of Q1 2026.
  • Ken Griffin bought 5,054 Sagimet Biosciences shares in Q1 2026, an estimated $28.2K.
  • Sagimet Biosciences made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #10083 holding.
  • Ken Griffin first reported a position in Sagimet Biosciences in Q3 2023 and has held it in 10 quarters since.
  • Ken Griffin's Sagimet Biosciences position peaked at $4.09M in Q2 2024.
  • 88 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.